Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery

Younis Baqi*, Christa E. Müller

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Citations (SciVal)


The P2Y12 receptor is one of eight known P2Y receptor subtypes, and belongs to the G-protein-coupled receptor (GPCR) family. The P2Y12 receptor is highly expressed on blood platelets and in the brain. Potent, selective, peripherally acting antagonists for the P2Y12 receptor are used clinically as antithrombotic drugs. Several different scaffolds have been identified as P2Y12 receptor antagonists, including irreversibly acting thienotetrahydropyridines (prodrugs), and reversible competitive antagonists, including adenine nucleotide analogs, piperazinyl-glutamate-quinolines, -pyridines, and -pyrimidines, and anthraquinone derivatives. Here, we provide an overview of the different scaffolds that have been developed as P2Y12 receptor antagonists, some of which have become important therapeutics.

Original languageEnglish
JournalDrug Discovery Today
Publication statusPublished - 2019

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery'. Together they form a unique fingerprint.

Cite this